BANGKOK, Sept. 3, 2024 /PRNewswire/ -- CJ Foods has announced the launch of its new high-protein snack, O-right Tempeh Chips, in Thailand. Its name combines the "O" shape of the chips with the idea of being made in a "right" way.
This innovative snack is made from Tempeh, a traditional Indonesian fermented soybean food. Each bag provides 6g of plant-based protein and contains no artificial coloring or preservatives. Available in four flavors – K-BBQ, Kimchi, Sriracha, and Truffle & Cheese – the K-BBQ and Kimchi flavors are tailored specifically to the taste of Thai consumers who have shown growing interest in Korean food. The aromatic and crispy O-right Tempeh Chips are ideal for any occasion, including pre & post workout, family gatherings, gaming sessions, and movie nights.
The chips are currently available on Shopee and Lazada, as well as at supermarket chains like Villa Market and Dear Tummy. CJ Foods plans to expand distribution to more supermarkets and hypermarkets, including Gourmet Market, Tops, and Big C within September, with a goal to reach 7-Eleven stores by the end of the year.
With O-right Tempeh Chips, CJ Foods aims to introduce healthier snack options to the Thai market, which has traditionally been dominated by potato chips, and to attract younger consumers. The company is engaging in various marketing activities through TikTok, Facebook, and Instagram to boost visibility.
"We are thrilled to bring the delicious and nutritious O-right Tempeh Chips to the Thai market," said a CJ Foods spokesperson. "Our goal is to expand distribution aggressively and establish the product as a popular choice among trend savvy and health-conscious consumers."
With the launch of the O-right Tempeh Chips following the success of bibigo Korean foods, CJ Foods is poised to accelerate its business expansion in Thailand. After entering the local market in 2023 through a joint venture with A-Best, a fruit and vegetable distribution company, CJ Foods has actively promoted its global Korean food brand bibigo through experiential events at major malls like Siam Paragon and ICONSIAM, as well as in night markets. CJ currently offers popular bibigo products such as dumplings, kimchi, seaweed, and K-sauces in Lotus's, Big C, Tops, Gourmet Market, Villa Market, and Dear Tummy.
About bibigo
Launched in 2010, bibigo is a global Korean food brand of CJ Foods. Aiming to enrich today's busy and demanding life, bibigo delivers K-food and culture to dinner tables worldwide under the new slogan "bibigo, live delicious." To bibigo, warm and delicious food is not just a meal, but a way to make life taste better. With its high-quality food products rooted in Korean passion, bibigo helps consumers make the most out of every moment.
The brand line-up includes a full assortment of snacks, appetizers and meal items. bibigo products are sold across around 60 countries globally, and the brand's signature item "Mandu" is sold in 6 continents.. Inspired by authentic recipes, bibigo makes the tastes of Korean cuisine accessible with popular offerings in most major grocery chains.
For more information, visit http://www.bibigo.com/en/at-home
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CJ Foods Launched Nutrient-rich O-right Tempeh Chips
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
